A simple and straightforward technique for coating microplate wells with molecularly imprinted polymer nanoparticles (nanoMIPs) to develop ELISA type assays is presented here for the first time. NanoMIPs were synthesized by a solid phase approach with immobilized vancomycin (template) and characterized using Biacore 3000, dynamic light scattering and electron microscopy. Immobilization, blocking and washing conditions were optimized in microplate format. The detection of vancomycin was achieved in competitive binding experiments with a HRP-vancomycin conjugate. The assay was capable of measuring vancomycin in buffer and in blood plasma within the range 0.001-70 nM with a detection limit of 0.0025 nM (2.5 pM). The sensitivity of the assay was three orders of magnitude better than a previously described ELISA based on antibodies. In these experiments nanoMIPs have shown high affinity and minimal interference from blood plasma components. Immobilized nanoMIPs were stored for 1 month at room temperature without any detrimental effects to their binding properties. The high affinity of nanoMIPs and the lack of a requirement for cold chain logistics make them an attractive alternative to traditional antibodies used in ELISA.
INTRODUCTION
Immunoassays are routinely used in the clinical, environmental, agricultural/food and forensic industries for the analysis of proteins, hormones, viruses, microorganisms, DNA sequences and drugs. 1, 2 The enzyme-linked immunosorbent assay (ELISA) is probably the most commonly used method. In this format competition between the free analyte and an enzyme-labeled conjugate for binding to immobilized antibodies is used for quantitative determination of the analyte. The enzyme label reveals how much displacement has occurred by a colorimetric reaction, amplified by multiple turnovers of the enzymatic reaction. 3 Immunoassays are rapid, sensitive and selective to the analyte of interest and are generally cost effective for large sample loads. However, as with any technology there are disadvantages; for example, the stability of reagents, the need for refrigerated transport and storage, batch to batch (or clone to clone) variability and the high cost of producing antibodies are often cited as problems.
In this regard molecularly imprinted polymers (MIPs) have already been identified as stable mimics of receptors or enzymes, suitable for use as substitutes for natural receptor molecules in assays or sensors. [4] [5] [6] Their inherent stability, low cost, short development time and ease of preparation offer several major advantages over antibodies. MIPs however, are perceived to have several shortcomings. Among these are a heterogeneous distribution of binding sites, which is responsible for high levels of non-specific binding and the complex procedures required for their immobilization at surfaces. In particular, the absence of a reproducible method for coating microplate wells with MIPs restricts their application in assays where this format is preferred.
Recently several examples of the application of MIPs to microplate-based assays have been described. [7] [8] [9] [10] [11] [12] [13] [14] [15] Only a few of these examples however actually involved the application of MIPs to enzyme-linked assays for quantitative detection of the template. [7] [8] [9] [10] In the first of these, the 4 surfaces of microplate wells were modified with a homopolymer of 3-aminophenylboronic acid, which was imprinted with epinephrine. The MIP-coated microplate was used successfully in an enzyme-linked assay for the detection of epinephrine at micromolar concentrations. That there are so few examples of MIP-based microplate assays can be due to several reasons: firstly the MIPs used in these assays resemble polyclonal antibodies, giving rise to high levels of nonspecific binding. Secondly, their manufacture relies on manual, labor-intensive methods of synthesis. Thirdly, the immobilization protocols are often complex, affecting the reproducibility of their synthesis and hence the potential for a high degree of variability between measurements.
Lastly, the developed MIP-based assays were not generic and required substantial modification to the analytical procedures traditionally used in ELISA. With the aim of resolving some of these problems, we recently developed a method for the solid-phase synthesis of MIP nanoparticles with pseudo-monoclonal binding properties. 16 Recently examples of protocols for synthesis of MIP nanoparticles have been reported by several research groups. [17] [18] [19] Here the MIP nanoparticles, synthesized in a computer-controlled reactor, were soluble in water and in organic solvents, and had uniform binding sites and high affinity to a range of targets used as the 20, 21 This measurement can however be affected by particle aggregation occurring via non-specific mechanisms (interactions with paraproteins), which can lead to an underestimate of the concentration in plasma. 21 More accurate measurements can be achieved using ELISA, since this does not depend on particle aggregation. There are however very few examples of ELISA for vancomycin 22 which justifies the importance of the development of novel assays. 
MATERIALS AND METHODS

Materials
Synthesis of MIP nanoparticles (nanoMIPs) imprinted with vancomycin
Preparation of vancomycin-derivatized glass beads The protocol for the immobilization of vancomycin on glass beads has already been described elsewhere. 16, 24 Briefly glass beads were activated by boiling them in NaOH for 10 min and washed with double-distilled water followed by acetone and then dried. 16 Finally, the glass beads were washed with double-distilled water, dried under vacuum and stored at 4°C until used.
Automated synthesis of vancomycin MIP nanoparticles (nanoMIPs) An upgraded automated
reactor as compared to the one used previously, 16 was utilized for the synthesis of the nanoparticles. The reactor, manufactured by HEL Ltd., (Borehamwood, UK), was designed such that both photochemically-and chemically-initiated polymerizations can be performed. All processes were performed under computer control, requiring minimal intervention from the operator. For the preparation of nanoMIPs specific for vancomycin, the polymerization mixture consisted of NIPAM (39 mg), BIS (2 mg), TBAm (33 mg dissolved in 2 mL of ethanol) and AA (2.23 g). The components were dissolved in double distilled water (100 ml), sonicated for 10 minutes and degassed by bubbling with nitrogen for 30 minutes. For the automated synthesis of nanoMIPs, the vancomycin functionalized glass beads, used as the solid-phase (60 g), were
added to the reaction cylinder. An aliquot of the polymerization mixture (60 mL) was added directly into the cylinder using a syringe pump and then stirred briefly to homogenize the contents. Polymerization was initiated by the addition of a solution of APS (60 mg mL -1 , 600 L) and TEMED (18 L) followed by stirring. The monomer mixture was allowed to polymerize at ambient temperature for 1.5 hours and during this time brief stirring (30 s at 600 RPM) was applied at the end of each 30 min period. After 90 min the polymerization mixture was drained from the reaction vessel using a combination of suction and nitrogen purging. Subsequently, water at ambient temperature (2 aliquots of 50 mL) was added to the cylinder, the contents stirred and the washings, containing unreacted monomers and other low affinity materials, removed and discarded. Next, a further 3 aliquots of water (50 mL each) were individually added to the cylinder and the temperature was raised to 60°C. At 60°C the non-covalent interactions between the template attached to the solid-phase and the high-affinity nanoMIPs were disrupted, thus allowing the pure fraction of particles, free of residual template and monomers, to be collected. This entire process took approximately 3.5 hours. The stages of this synthesis were pre-programed into the WinISO® software such that, once started, the synthesis could be left to run without the necessity for user supervision. The solution of MIP nanoparticles was concentrated to a final volume of 100 mL by ultrafiltration on a Millipore Amicon Ultra centrifugal filter unit (30 kDa MWCO), and used for development of the biomimetic ELISA.
Analysis of the size of MIP nanoparticles
The size of the nanoparticles was determined by dynamic light scattering (DLS) using a Zetasizer Nano (Nano-S) from Malvern Instruments Ltd (Malvern, UK) and from images obtained on a Philips CM20 Transmission Electron Microscope (TEM). Prior to DLS measurements the solution of nanoMIPs was subjected to sonication for 5 minutes and measurements were performed at 25°C. Prior to TEM analysis the solution of nanoMIPs was 8 sonicated for 2 minutes after which a drop of the nanoMIP solution was placed on a carboncoated copper grid and dried in air.
Preparation of the HRP-vancomycin (HRP-V) conjugate
HRP (10 mg) was dissolved in 0.1 M MES buffer, pH 6 (1 mL), to which EDC (0.4 mg), followed by NHS (0.6 mg) were added. The reaction was allowed to proceed at room temperature for 15 min. At this point the buffer was removed by ultrafiltration on a Millipore
Amicon Ultra centrifugal filter unit (30 kDa MWCO). Activated HRP was collected from the ultrafiltration unit and immediately incubated with vancomycin (10 mL, 1 mg mL -1 ) in PBS buffer at pH 7.4 for 2 hours. The HRP-vancomycin conjugate (HRP-V) was then washed to remove free vancomycin on a Millipore Amicon Ultra centrifugal filter unit (30 kDa MWCO).
For this 10 washes with PBS (5 mL) were performed. After washing, the conjugate was dissolved in deionized water (2 mL), its concentration estimated by comparison with the enzymatic activity of the free enzyme and stored frozen at -18°C until use. This was used as the stock solution in the procedures described below.
Immobilization of nanoMIPs onto the surface of microplate wells
Vancomycin-imprinted nanoparticles (40 L, 0.056 mg mL -1 ) were dispensed into the wells of a 96-well microplate and the solvent (water) allowed to evaporate overnight at room temperature.
Optimization of assay conditions
Several parameters such as the composition of the blocking and washing buffers, quantity of nanoMIPs, time of incubation and concentration of HRP-V were optimized in order to find the best conditions for the competitive assay. For the optimization of the quantity of nanoMIPs, microplates were prepared, as described above, by dispensing a standard volume of a solution of vancomycin-imprinted nanoMIPs (40 L) of different concentrations (from the stock concentration, 0.056 mg mL -1 to a 10-fold dilution) into the test wells. Evaporation of the solvent and performance of the blank assay (noncompetitive, in absence of free vancomycin) were as described above, using the previously optimized blocking and washing conditions. The optimum quantity of nanoparticles was determined to be that which gave the greatest difference in color development between experiments conducted with HRP and HRP-V. The highest concentration (0.056 mg mL -1 ) was selected and used in subsequent experiments.
For the optimization of the concentration of the conjugate (HRP-V), the blank assay was performed under the previously optimized conditions using different concentrations of HRP-V or HRP by diluting stock solutions from 1:200-to 1:1600-fold. The optimum concentration of the conjugate was determined to be that which gave the greatest difference in color development between experiments conducted with HRP and HRP-V. Dilution of the stock solution 1 in 800 was judged to be optimum and this concentration was used in subsequent experiments.
For the optimization of the incubation time of the conjugate, the blank assay was repeated under the previously optimized conditions using different times (30 min, 1 h or 2 h) for the incubation of HRP-V or HRP with the nanoMIP-coated microplate wells before washing and color development. The minimum incubation time required to maximize color development in the case of the conjugate compared to HRP alone was determined to be 1 h. This incubation time was used in all subsequent experiments.
Competitive assay
Following optimization of the assay conditions, the final protocol was then tested in a competitive assay conducted as follow: Microplate wells were coated with nanoMIPs by dispensing undiluted stock solution (40 L) into each well followed by evaporation overnight. 
Analysis of vancomycin in plasma
For use in the following experiments, plasma was extracted from porcine blood, sourced from a local butcher, by centrifugation at 2,500 rpm (1,201g) for 30 minutes to remove the cellular components. The clear supernatant was then collected and stored in the freezer at -20°C until use. In order to demonstrate the analysis of vancomycin in biological media, the porcine plasma was spiked (6-50 M) with vancomycin at levels spanning the clinically relevant concentration range. Plasma samples were then diluted 100,000-fold to fall within the calibration range of the competitive assay. Vancomycin concentrations in plasma were determined by analysis using the competitive assay described above. The concentration of vancomycin in plasma was calculated using the absorbance values read for the samples and the equation of the calibration curve obtained with the standards.
Cross-reactivity of the nanoMIP-based assay
To assess the cross-reactivity of nanoMIP-based assay, the competitive assay was performed with three other commonly used antibiotics (gentamicin, bleomycin and amoxicillin) over the concentration range 0.01-70 nM.
Stability of the nanoMIP-coated microplates
To assess the stability of microplate wells coated with nanoMIPs, several microplates were prepared as described above and subjected to the following storage trials: 1 month at room temperature or one week at 40°C in a humid environment. In each case this was followed by periodic testing by competitive assay for vancomycin, as described above.
RESULTS AND DISCUSSION
The synthesis of MIP nanoparticles (nanoMIPs) for vancomycin was performed using an automated solid-phase synthesis approach, as described earlier. 16 Vancomycin was immobilized through its amino group by glutaraldehyde coupling to the surface of amine-derivatized glass beads which served as the template in nanoMIP synthesis. The polymer composition for the preparation of nanoMIPs was adapted from that published by Hoshino et al. 25 The interaction between the imprinted polymer and the glycopeptide antibiotic is due to a combination of multiple weak electrostatic and hydrophobic interactions. The concentration of nanoparticles present in the stock solution (100 mL) was determined to be 0.056 mg mL The apparent dissociation constant for the interaction between vancomycin-imprinted nanoMIPs and vancomycin immobilized on the surface of gold chips was determined by surface plasmon resonance using a Biacore 3000, as previously described, 16 see Figure S1 in Supporting Information. The apparent dissociation constant was determined to be 0.48 nM.
In order to develop a quantitative assay analogous to ELISA, using MIP nanoparticles in place of antibodies, a simple immobilization procedure was required to be developed for the deposition of stable coatings of nanoMIPs on the surface of microplate wells. In ELISA, antibodies are frequently immobilized through physical adsorption to the walls of polystyrene microplates by hydrophobic binding. Previous MIP-based assays performed in microplates however, relied on in situ formation of the imprinted material through polymerization in the test wells. [7] [8] [9] [10] In our case we set out to show that MIP nanoparticles, previously prepared by solidphase synthesis, 16 
with EDC-NHS to form the HRP-vancomycin conjugate (HRP-V). After conjugation
the concentration of HRP-V was estimated to be 2.5 mg mL -1 by comparing its enzymatic activity with that of the free enzyme. A calibration curve of HRP-V and HRP for different dilutions of the substrate (TMB reagent) was also performed to ensure that the activity of the enzyme had not been compromised during conjugation. The results reported in Figure S2 show that there was no deterioration in the enzymatic activity of HRP-V, as the two calibration curves appeared to be nearly identical.
To establish that the immobilized nanoMIP layer retained affinity for vancomycin, coated wells were incubated with HRP-V, followed by washing and color development by reaction with TMB. Uncoated wells were similarly treated as a control. As an additional test of specificity, we also compared the binding of HRP-V to non-imprinted nanoparticles or nanoNIPs. In actuality these were nanoparticles imprinted with trypsin, synthesized under the same conditions, using the same composition as the vancomycin nanoMIPs, but using a trypsin-coated solid phase. The results, reported in Figure 2 , show that much higher binding of HRP-V was seen in the case of the nanoMIPs than either with nanoNIPs or with bare wells. Errors in the absorbance measurements represent ± 1 standard deviation and are for experiments performed in triplicate.
The table shows that the most dilute solutions (1:800 and 1:1600) produced the greatest differences between the binding of HRP-V and HRP to the nanoparticles. The 1:800 dilution was preferred however, as this allowed acceptable levels of color development to be achieved from between 10 to 30 minutes.
The optimized protocol was then applied to the performance of a competitive assay.
Microplates, coated with vancomycin-imprinted nanoMIPs were tested in an enzyme-linked assay using competition between free vancomycin and the HRP-V conjugate. The concentration of free vancomycin was varied between 1 pM to 70 nM, added to the wells at the same time as With concentrations of vancomycin on a logarithmic scale, the assay showed linearity from 1 pM to 70 nM, with a limit of detection of 2.5 pM, calculated from the value of three times the standard deviation of the control (without free vancomycin). This is much lower than the detection limit of the immunoassay reported in the literature, which was only 0.1 M. 22 The sensitivity range demonstrated in this assay is in agreement with the value of the apparent dissociation constant for the interaction of the imprinted nanoparticles with vancomycin, as determined in experiments conducted on the Biacore (K D = 0.48 nM). The competitive assay started to show saturation at concentrations of vancomycin higher than 70 nM.
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The cross-reactivity of the assay was measured by assessing the response to other commonly used antibiotics: amoxicillin, gentamicin and bleomycin and the results presented in Figure 5 . These tests, together with the large difference in binding of the HRP-V conjugate to nanoMIPs and nanoNIPs (see Figure 2 ) clearly indicate the highly specific affinity of the imprinted nanoparticles for their template, which in this respect resembles the behavior of monoclonal antibodies.
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Further experiments were performed in order to evaluate the stability of the nanoparticles and the coatings prepared from them. Binding of HRP-V to the MIP was evaluated in repeat measurements carried out during a period of one month. It was found that throughout this period the polymer retained its original activity and could still be used in an assay. As a test of the stability of coatings, nanoMIP-coated microplates were stored at 40°C for 1 week to mimic unrefrigerated transportation and delivery to tropical countries (no cold chain). The results
showed that even when subjected to these conditions, the plates could still be used in the vancomycin assay over the same concentration range (0.001-70 nM), with no deterioration in the detection limit.
Finally, to demonstrate the clinical relevance of the developed assay, porcine plasma was spiked with vancomycin at a number of concentrations spanning the clinically relevant range: 6-35 M (10-50 mg/L) and subjected to the nanoMIP-based assay. The results demonstrated good correlation (mean recovery 98 ± 2.6 %) between the spike and concentrations of vancomycin measured in the assay (see Table 2 ). Clearly blocking of the nanoMIP-coated surfaces with protein and surfactant was sufficient to negate any impact that plasma components might have had on the analysis. The high sensitivity of the assay demanded extensive dilution of the serum samples which also helped to minimize potential interferences. 
CONCLUSIONS
This study demonstrates that molecularly imprinted nanoparticles (nanoMIPs), prepared by solid-phase synthesis, 16 can be used in the development of a new, highly specific and sensitive, clinically relevant enzyme-linked assay for a currently prescribed antibiotic (vancomycin). The assay formulation was based on ELISA, with the exception that nanoMIPs were used as a direct substitute for antibodies. Coating microplate wells with the soluble MIP nanoparticles was achieved by simply allowing the solutions to evaporate to dryness in the wells, equivalent to physical adsorption of antibodies. The developed assay allowed the accurate determination of vancomycin over the concentration range 0.001-70 nM, with a limit of detection of 0.0025 nM (2.5 pM). The assay could be used to determine vancomycin in plasma at clinically relevant concentrations with a mean accuracy of 98% and very low cross-reactivity with three other antibiotics. In this respect the performance of nanoMIPs was comparable to high quality monoclonal antibodies. Furthermore, we have demonstrated that the nanoMIP-coated 23 microplates can withstand exposure to high temperature for prolonged periods without affecting the sensitivity of the assay, suggesting that assays formulated in this manner do not require refrigeration during transportation and storage, which could have both social and economic benefits. While the assay presented here is for a specific analyte, vancomycin, the generic nature of nanoMIP preparation in solid-phase synthesis 16, 24, 26, 27 suggests that assays for many more analytes, including drugs, toxins, pesticides, pollutants, peptides, proteins, hormones, viruses and disease biomarkers, among others, can be created with relatively short development times. 
